公开(公告)号：US20240075129A1

公开(公告)日：2024-03-07

申请号：US18488629

申请日：2023-10-17

申请人： ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC分类号： A61K39/215 ,  C12N15/861

CPC分类号： A61K39/215 ,  C12N15/861 ,  A61P31/14

摘要： Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US11857620B2

公开(公告)日：2024-01-02

申请号：US17198164

申请日：2021-03-10

申请人： ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC分类号： A61K39/215 ,  A61K39/39 ,  C12N15/86 ,  A61P31/14 ,  A61K39/00

CPC分类号： A61K39/215 ,  A61K39/39 ,  C12N15/86 ,  A61K2039/545 ,  A61K2039/55505 ,  A61P31/14 ,  C12N2710/10343 ,  C12N2770/20022 ,  C12N2770/20034

摘要： Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US20220016234A1

公开(公告)日：2022-01-20

申请号：US17405393

申请日：2021-08-18

申请人： ImmunityBio, Inc.

发明人： Adrian Rice ,  Mohit Verma

IPC分类号： A61K39/215 ,  C12N1/16 ,  C07K14/165 ,  C07K14/005 ,  C12N15/86 ,  C07K14/81

摘要： Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), followed by administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion.

公开(公告)号：US20230338508A9

公开(公告)日：2023-10-26

申请号：US17198164

申请日：2021-03-10

申请人： ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC分类号： A61K39/215 ,  A61K39/39 ,  A61P31/14 ,  C12N15/86

CPC分类号： A61K39/215 ,  A61K39/39 ,  A61P31/14 ,  C12N15/86 ,  A61K2039/55505

摘要： Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

公开(公告)号：US20230086390A1

公开(公告)日：2023-03-23

申请号：US17198164

申请日：2021-03-10

申请人： ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Peter Sieling ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Lise Geissert ,  Annie Shin ,  Adrian Rice ,  Elizabeth Gabitzsch ,  Jeffrey Safrit ,  Leonard Sender

IPC分类号： A61K39/215 ,  A61K39/39 ,  A61P31/14 ,  C12N15/86

摘要： Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.